The potential of hepcidin/serum ferritin ratio in assessing anemia in patients with maintenance peritoneal dialysis

doi:10.3969/j.issn.1004-583X.2025.05.009

Abstract

Abstract:

Objective To investigate the value of hepcidin (HEP)/serum ferritin (SF) ratio in the evaluation of anemia in patients with maintenance peritoneal dialysis (PD). Methods A total of 238 PD patients who were regularly followed up in the PD Center of Linyi People 's Hospital from January 2020 to December 2021 were selected. There were 107 males and 131 females, with an average age of (50.21±13.92) years, and a median dialysis age of 16 months. According to the level of hemoglobin (HGB), patients were divided into the anemia group (HGB<110 g/L, n=130) and non-anemia group (HGB≥110 g/L, n=108). The clinical data of the two groups were compared. Pearson correlation analysis was performed on the relevant indicators. Multivariate logistic regression was used to analyze the risk factors for anemia in PD patients. The receiver operating characteristic (ROC) curve was drawn to evaluate the predictive value of HEP, SF and HEP/SF ratio in anemia among PD patients. Results Compared with the non-anemia group, the HEP and HEP/SF ratio in the anemia group were significantly higher, while SF was significantly lower (P<0.05). Pearson correlation analysis showed that SF was positively correlated with HGB (P<0.01), while HEP and HEP/SF ratio were negatively correlated with HGB (P<0.01). Logistic regression analysis showed that HEP, SF and HEP/SF ratio were independent risk factors for anemia in PD patients (P<0.05). ROC curve showed that the HEP/SF ratio was of great value in evaluating renal anemia in patients with maintenance PD, with an area under the curve (AUC) of 0.892 (95% confidence interval [CI]: 0.846-0.937, P<0.01). The optimal cut-off value was 0.63, with a sensitivity of 76.9%, and a specificity of 96.3%. Conclusion HEP, SF and HEP/SF ratio are independent risk factors for renal anemia in patients with maintenance PD that reflect the severity of anemia to a certain extent. They have certain evaluation value for renal anemia in patients with maintenance PD.

Key words: chronic kidney disease, peritoneal dialysis, anemia, hepcidin/serum ferritin

CLC Number:

R692

Zhang Hongtao, Zhong Meijiao, Gao Jingyang, Li Shijie, Yu Naxin, Fan Xin, Chen Lining, Zhang Yang, Wang Zhikui, Bian Aishu. The potential of hepcidin/serum ferritin ratio in assessing anemia in patients with maintenance peritoneal dialysis[J]. Clinical Focus, 2025, 40(5): 434-438.

Add to citation manager EndNote|Ris|BibTeX

URL: http://www.lchc.cn/EN/10.3969/j.issn.1004-583X.2025.05.009

http://www.lchc.cn/EN/Y2025/V40/I5/434

Figures/Tables 6

References 15

[1]	Costa E, Pereira BJ, Rocha-Pereira P, et al. Hepcidin as a predictor of response to iron therapy in peritoneal dialysis patients[J]. Nephrology, 2015, 20(8):534-540.
[2]	中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20):1463-1502.
[3]	王祎星, 马红珍. 肾性贫血的发生机制与治疗研究进展[J]. 浙江医学, 2018, 40(5):537-540.
[4]	Hanna RM, Streja E, Kalantar-Zadeh K. Burden of anemia in chronic kidney disease: Beyond erythropoietin[J]. Adv Ther, 2021, 38(1):52-75. doi: 10.1007/s12325-020-01524-6 pmid: 33123967
[5]	刘颖, 林洪丽. 慢性肾脏病贫血与炎症[J]. 中国实用内科杂志, 2020, 40(11):908-911. doi: 10.19538/j.nk2020110107
[6]	Babitt JL, Eisenga MF, Haase VH, et al. Controversies in optimal anemia management: Conclusions from a kidney disease: Improving global outcomes (KDIGO) conference[J]. Kidney Int, 2021, 99(6):1280-1295. doi: 10.1016/j.kint.2021.03.020 pmid: 33839163
[7]	Schömig M, Eisenhardt A, Ritz E. The microinflammatory state of uremia[J]. Blood Purif, 2000, 18(4):327-332.
[8]	Arosio P. New advances in iron metabolism, ferritin and hepcidin research[J]. Int J Mol Sci, 2022, 23(23):14700.
[9]	Tarancon-Diez L, Genebat M, Roman-Enry M, et al. Threshold ferritin concentrations reflecting early iron deficiency based on hepcidin and soluble transferrin receptor serum levels in patients with absolute iron deficiency[J]. Nutrients, 2022, 14(22):4739.
[10]	米海潮, 崔芳, 杜玉涛, 等. 慢性病贫血铁代谢调节机制的研究进展[J]. 生理学报, 2022, 74(4):639-647.
[11]	Nemeth E, Ganz T. Hepcidin and iron in health and disease[J]. Annu Rev Med, 2023, 74:261-277.
[12]	张泽宇, 尹良红. 缺氧诱导因子调节铁调素在肾性贫血中的研究进展[J]. 中国病理生理杂志, 2021, 37(3):558-564.
[13]	Prabhu MV, Nayak A, Sridhar G, et al. Maximizing the erythropoietin response: Iron strategies[J]. Contrib Nephrol, 2012, 178:95-99. doi: 10.1159/000337820 pmid: 22652723
[14]	鲍美霜, 王洁, 肖宇, 等. Hepcidin/SF比值在维持性腹膜透析患者中的临床价值分析[J]. 右江民族医学院学报, 2021, 43(6):751-756.
[15]	滑瑞雪, 邹陆曦, 吴雨, 等. 透析液葡萄糖对维持性血液透析患者血清铁调素合成的影响[J]. 临床肾脏病杂志, 2022, 22(5):359-364.

项目	非贫血组(n=108)	贫血组(n=130)	t/Z值	P值
透析龄(月)	21.23±11.59	20.62±13.89	0.367	0.714
收缩压(mmHg)	144.56±21.12	143.77±24.20	0.271	0.787
PLT(×10⁹/L)	220.00±70.36	220.13±84.09	-0.013	0.990
RDW(fL)	44.90±5.39	44.90±6.27	0.002	0.998
ALB(g/L)	36.39±7.12	34.73±6.61	1.861	0.044
UCB(μmol/L)	5.13±2.85	4.63±2.42	1.470	0.143
ALP(U/L)	89.30±50.03	85.76±48.37	0.551	0.582
PAB(mg/L)	30.68±8.72	32.01±9.97	-0.790	0.431
BUN(mmol/L)	23.44±7.00	25.25±7.60	-1.884	0.061
UA(μmol/L)	396.38±98.40	404.54±115.71	-0.580	0.563
TC(mmol/L)	4.93±1.34	4.68±1.39	1.410	0.160
LDL-C(mmol/L)	3.07±1.04	2.92±1.01	1.090	0.277
K⁺(mmol/L)	4.37±0.82	4.37±0.69	0.092	0.927
CO₂(mmol/L)	23.87±4.22	23.81±4.02	0.122	0.903
P(mmol/L)	1.77±0.61	1.89±0.52	-1.619	0.107
总CCr(ml/min)	66.80±27.14	62.96±17.67	0.734	0.465
腹膜CCr(ml/min)	38.01±16.34	42.75±16.94	-1.250	0.215
NE(×10⁹/L)	4.6(3.5, 6.4)	4.5(3.6, 6.3)	-0.080	0.936
CB(μmol/L)	2.0(1.4, 2.7)	1.7(1.3, 2.4)	-1.924	0.054
AST(U/L)	16.3(11.8, 21.1)	15.1(11.7, 21.3)	-0.462	0.644
ALT(U/L)	12.0(8.4, 17.8)	11.1(7.2, 18.1)	-0.912	0.362
FPG(mmol/L)	5.6(5.0, 6.6)	5.4(4.8, 7.1)	-0.364	0.716
TG(mmol/L)	1.3(0.9, 1.9)	1.2(0.8, 1.6)	-1.701	0.089
PTH(ng/L)	192.8(93.7, 385.0)	253.9(133.6, 480.9)	-1.857	0.063
HEP(μg/L)	79.80±7.58	112.33±32.12	-11.181	0.020
SF(μg/L)	240.52±68.74	120.67±71.86	13.063	0.038
HEP/SF比值	0.37±0.14	1.45±1.05	-11.612	0.041

项目	非贫血组(n=108)	贫血组(n=130)	t/Z值	P值
透析龄(月)	21.23±11.59	20.62±13.89	0.367	0.714
收缩压(mmHg)	144.56±21.12	143.77±24.20	0.271	0.787
PLT(×10⁹/L)	220.00±70.36	220.13±84.09	-0.013	0.990
RDW(fL)	44.90±5.39	44.90±6.27	0.002	0.998
ALB(g/L)	36.39±7.12	34.73±6.61	1.861	0.044
UCB(μmol/L)	5.13±2.85	4.63±2.42	1.470	0.143
ALP(U/L)	89.30±50.03	85.76±48.37	0.551	0.582
PAB(mg/L)	30.68±8.72	32.01±9.97	-0.790	0.431
BUN(mmol/L)	23.44±7.00	25.25±7.60	-1.884	0.061
UA(μmol/L)	396.38±98.40	404.54±115.71	-0.580	0.563
TC(mmol/L)	4.93±1.34	4.68±1.39	1.410	0.160
LDL-C(mmol/L)	3.07±1.04	2.92±1.01	1.090	0.277
K⁺(mmol/L)	4.37±0.82	4.37±0.69	0.092	0.927
CO₂(mmol/L)	23.87±4.22	23.81±4.02	0.122	0.903
P(mmol/L)	1.77±0.61	1.89±0.52	-1.619	0.107
总CCr(ml/min)	66.80±27.14	62.96±17.67	0.734	0.465
腹膜CCr(ml/min)	38.01±16.34	42.75±16.94	-1.250	0.215
NE(×10⁹/L)	4.6(3.5, 6.4)	4.5(3.6, 6.3)	-0.080	0.936
CB(μmol/L)	2.0(1.4, 2.7)	1.7(1.3, 2.4)	-1.924	0.054
AST(U/L)	16.3(11.8, 21.1)	15.1(11.7, 21.3)	-0.462	0.644
ALT(U/L)	12.0(8.4, 17.8)	11.1(7.2, 18.1)	-0.912	0.362
FPG(mmol/L)	5.6(5.0, 6.6)	5.4(4.8, 7.1)	-0.364	0.716
TG(mmol/L)	1.3(0.9, 1.9)	1.2(0.8, 1.6)	-1.701	0.089
PTH(ng/L)	192.8(93.7, 385.0)	253.9(133.6, 480.9)	-1.857	0.063
HEP(μg/L)	79.80±7.58	112.33±32.12	-11.181	0.020
SF(μg/L)	240.52±68.74	120.67±71.86	13.063	0.038
HEP/SF比值	0.37±0.14	1.45±1.05	-11.612	0.041

变量	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
HEP	0.052	0.007	54.087	0.040	1.053	1.039~1.068
SF	-0.022	0.003	63.590	0.021	0.979	0.973~0.984
HEP/SF比值	6.632	0.956	48.102	0.039	759.118	116.505~4 946.210

变量	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
HEP	0.052	0.007	54.087	0.040	1.053	1.039~1.068
SF	-0.022	0.003	63.590	0.021	0.979	0.973~0.984
HEP/SF比值	6.632	0.956	48.102	0.039	759.118	116.505~4 946.210

项目	平均值	标准差	HGB	HEP	SF	HEP/SF比值
HGB	103.845	19.133	1
HEP	97.567	29.169	-0.468^*	1
SF	175.053	92.301	0.840^*	-0.477^*	1
HEP/SF比值	0.960	0.951	-0.760^*	0.608^*	-0.806^*	1